Alec J. Barclay
Net Worth
Last updated:
What is Alec J. Barclay net worth?
The estimated net worth of Mr. Alec J. Barclay is at least $4,074,122 as of 8 Apr 2022. He owns shares worth $2,274 as insider, has earned $42,998 from insider trading and has received compensation worth at least $4,028,850 in T2 Biosystems, Inc..
What is the salary of Alec J. Barclay?
Mr. Alec J. Barclay salary is $575,550 per year as Chief Operations Officer in T2 Biosystems, Inc..
How old is Alec J. Barclay?
Mr. Alec J. Barclay is 45 years old, born in 1980.
What stocks does Alec J. Barclay currently own?
As insider, Mr. Alec J. Barclay owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| T2 Biosystems, Inc. (TTOO) | Chief Operations Officer | 181,944 | $0.01 | $2,274 |
What does T2 Biosystems, Inc. do?
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Alec J. Barclay insider trading
T2 Biosystems, Inc.
Mr. Alec J. Barclay has made 4 insider trades between 2018-2022, according to the Form 4 filled with the SEC. Most recently he purchased 12,951 units of TTOO stock worth $6,476 on 8 Apr 2022.
The largest trade he's ever made was exercising 168,488 units of TTOO stock on 24 Feb 2022. As of 8 Apr 2022 he still owns at least 181,944 units of TTOO stock.
T2 Biosystems key executives
T2 Biosystems, Inc. executives and other stock owners filed with the SEC:
- Mr. Alec J. Barclay (45) Chief Operations Officer
- Mr. John J. Sperzel III, B.Sc. (62) Chairman & Chief Executive Officer